Find suitable products, scientific resources or answers to your questions within our technical library FAQ.

  • Home
  • Search results for: 'news press releases for faster research on immunotherapies hla typed human primary cells'

Search results for: 'news press releases for faster research on immunotherapies hla typed human primary cells'

Items 1-12 of 156 Results

  • For faster research on immunotherapies: HLA-typed human primary cells

    – HLA-typed human primary cells for researchers across the world – Great tool in the development and testing of new cancer drugs – HLA-typed donor characteristics are precisely documented… Go To Page

  • HLA class II typed cells to accelerate effective research on immunotherapies

    We support effective research on immunotherapies by expanding the range of HLA-types provided for all Human Primary Cells and Blood & Stem Cells. In addition to the MHC class I genes HLA-A, -B, and -C, we now also offer 4-digit resolution for MHC class II genes HLA-DPA1/DPB1, -DQA1/DQB1, and -DRB1/DRB345. The Human Leukocyte Antigen (HLA) system plays a fundamental role in the determination of histocompatibility between different individuals and regulation of the human immunity…. Go To Page

  • Histocompatibility: Piecing together the immunotherapy puzzle

    What do puzzles and immunity have in common? The human leukocyte antigen (HLA) system of cell-surface proteins help to regulate the immune system. Yet particular antigens can make a crucial difference. Patients with certain HLA types are more likely to have autoimmune diseases, contract infectious disease or develop cancer. Now, through better understanding of HLA function,… Go To Page

  • The importance of HLA for the development of cell therapies

    Thanks to a greater understanding of human leukocyte antigen (HLA) function, researchers can now work toward developing new cancer immunotherapies…. Go To Page

  • Immuno-oncology

    A new in vitro strategy Immuno-oncology is a unique combination of oncology and immunology. By activating or amplifying the body’s natural defenses, immuno-oncology aims to boost the immune system to fight cancer better. Targeted antibodies or immunomodulators are well-known immunotherapies; adoptive cell therapy using CAR-T or TCR cells is particularly important,… Go To Page

  • Teaching the body to fight tumors using cancer immunotherapy

    Selected as the 2013 “Breakthrough of the Year” by Science magazine, cancer immunotherapy shows a completely new way to treat malignancies by using the body’s own immune system, and not by targeting the tumor itself. This cutting-edge area of research and therapy has shown very promising results. However, further investigation is needed to turn immunotherapy into a cancer therapy that can be broadly applied…. Go To Page

  • CSC therapy – towards new opportunities

    CSCs as therapeutic targets Cancer stem cells (CSCs) are a small subset of tumor cells that are able to evade anti-tumor defense mechanisms and suppress anti-tumor immune responses by releasing soluble immunosuppressive factors, such as anti-inflammatory cytokines. CSCs appear to have multiple strategies to escape immunological destruction, including the acquisition of genetic and non-genetic alterations that reduce immune recognition,… Go To Page

  • Cell expansion service

    Our custom cell expansion service can be of great help in your research. Depending on the requirements of the field of your research (e.g., RNA-seq, high-throughput screening for drug discovery, toxicity screening for immunotherapy development), large numbers of primary cells are inevitable. Upscaling your cell culture in-house can be challenging for many reasons…. Go To Page

  • PromoCell now exclusive supplier of MATra (Magnet-Assisted Transfection)

    Primary cells can prove much more difficult to transfect than other commonly used cell lines. While high transfection efficiencies are possible using commercially available transfection reagents in diverse, commonly used cell lines, primary cells but also diverse cell lines have proven much more difficult to transfect…. Go To Page

  • Could HLA-type be the answer to individual differences in COVID-19 severity?

    The COVID-19 pandemic has changed the world. While vaccines are now being approved, a true understanding of the biological processes underlying COVID-19 and why some individuals develop severe disease while others are asymptomatic is necessary. HLA-type could be a key differentiator in disease outcomes, and in developing treatments…. Go To Page

  • Invisible attraction: Using magnets to develop drugs in cell cultures

    Modern medicines are high-tech products. Developing medicines increasingly includes high throughput screening by fully automated analysis robots. One exciting high throughput approach uses magnetic 3D cell culture – which provides a more realistic model of human tissue than with 2D cell culture. The later a candidate drops out, the more expensive it is…. Go To Page

  • Tumor microenvironment

    The role of CSCs and the TME Cellular interactions in the tumor microenvironment (TME) significantly influence cancer progression and drug response. The efficacy of immunotherapies has triggered increased interest in the tumor immune microenvironment. Therefore, robust experimental systems are needed to enable researchers to model patient-specific interactions between tumor cells and immune cells…. Go To Page

Choose your region

Copyright © 2013-present Magento, Inc. All rights reserved.